GLP-1 and multi-receptor agonists in metabolic research.
Modern metabolic research is built around incretin biology. Agonists of the GLP-1, GIP and glucagon receptors change gastric emptying, insulin sensitivity, satiety and energy expenditure. Studies read out fasting glucose, HOMA-IR, body weight, body composition and hepatic fat content.
Semaglutide is a long-acting GLP-1 receptor agonist. It slows gastric emptying and acts on hypothalamic satiety circuits to reduce intake. Studies focus on dose escalation, nausea adaptation curves and weight trajectory across a 16 to 68 week window.
Tirzepatide co-activates the GLP-1 and GIP receptors. The GIP component tunes adipocyte insulin sensitivity and fat storage dynamics, and adds to GLP-1 satiety. Studies show that at matched caloric intake, body composition and hepatic fat outcomes exceed GLP-1 alone.
Retatrutide is a triple agonist. Its glucagon component directly raises resting energy expenditure and hepatic fat oxidation. Studies focus on longer-term cardiovascular markers, hepatic fat clearance rate and interaction with training and protein intake.
Reference only for researchers in compliant settings.
For research use only. Not medical advice. Not for diagnosis or treatment.
